Abstract
Purpose To investigate whether circulating-tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease.
Experimental Design We present full follow-up results (median follow-up: 68 months) from a previously described cohort of 68 neoadjuvant chemotherapy (NAC)-treated patients who underwent longitudinal ctDNA testing (712 plasma samples). In addition, we performed ctDNA evaluation of 153 plasma samples collected before and after radical cystectomy (RC) in a separate cohort of 102 NAC-naïve patients (median follow-up: 72 months). Total RNA-sequencing of tumors was performed to investigate biological characteristics of ctDNA shedding tumors.
Results Assessment of ctDNA after RC identified metastatic relapse with a sensitivity of 94% and specificity of 98% using the expanded follow-up data for the NAC-treated patients. ctDNA dynamics during NAC was independently associated with patient outcomes when adjusted for pathological downstaging (HR=4.7, p=0.029). For the NAC-naïve patients, ctDNA was a prognostic predictor before (HR=3.4, p=0.0005) and after RC (HR=17.8, p=0.0002). No statistically significant difference in recurrence-free survival for patients without detectable ctDNA at diagnosis was observed between the cohorts. Baseline ctDNA positivity was associated with the Ba/Sq subtype and enrichment of epithelial-to-mesenchymal transition and cell-cycle associated gene sets.
Conclusions ctDNA is prognostic in NAC-treated and NAC-naïve patients with more than five years follow-up and outperforms pathological downstaging in predicting treatment efficacy. Patients without detectable ctDNA at diagnosis may benefit significantly less from NAC, but additional studies are needed.
Competing Interest Statement
Lars Dyrskjøt has sponsored research agreements with Natera, C2i Genomics, AstraZeneca, Photocure, and Ferring and has an advisory/consulting role at Ferring, MSD and UroGen. Lars Dyrskjøt has received speaker honorar from AstraZeneca, Pfizer and Roche and is board member in BioXpedia. Jørgen Bjerggaard Jensen is proctor for Intuitive Surgery, is a member of advisory board for Olympus Europe, Ambu, Cepheid, Janssen, and Ferring and has sponsored research agreements with Medac, Photocure ASA, Cepheid, Olympus, and Ferring. George Laliotis, Derrick Renner, Shruti Sharma, Adam ElNaggar, Minetta C. Liu, Himanshi Sethi, Alexey Aleshin are all employees of Natera and hold stocks in the company. Additional COIs for Adam ElNaggar: Consulting/Advisory role for EMD Serano and GSK. Additional COIs for Minetta C. Liu: Grants/Contracts: Funding to Institution (Mayo) from: Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics, Tesaro; Travel Support Reimbursement from AstraZeneca, Genomic Health, Ionis; Ad hoc advisory board meetings. All funds to Mayo Clinic. No personal compensation from: AstraZeneca, Celgene, Roche/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics, Syndax.
Funding Statement
This work was funded by research grants to Lars Dyrskjøt from The Novo Nordisk Foundation, The Independent Research Council Denmark, Aarhus University, and Aarhus University Hospital; Sia Viborg Lindskrog from NEYE Foundation, Gangstedfonden, Cancerlivfonden, Tømrermester Jørgen Holm og hustru Elisa F. Hansens Mindelegat, Direktør Jacob Madsen og hustru Olga Madsens Fond, Slagtermester Max Wørzner og hustru Wørzners Mindelegat. Furthermore, the work was supported by the Danish Cancer Biobank.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Danish National Committee on Health Research Ethics gave ethical approval for this work (#1302183 and #1706291).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The raw sequencing data generated in this study are not publicly available as this compromises patient consent and ethics regulations in Denmark. Processed non-sensitive data are available upon reasonable request from the corresponding author.
